コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 2-SMe-ADP(alpha-S), 7A, as a most promising neuroprotectant.
2 Hence, we propose 7A as a highly promising neuroprotectant.
3 sodium channels, was initially proposed as a neuroprotectant.
4 Hence, we propose 7a as a highly promising neuroprotectant.
5 llin (Cryab), an endogenous immunomodulatory neuroprotectant.
6 have potential as an effective and nontoxic neuroprotectant.
7 CS1 and as a consequence is able to act as a neuroprotectant.
8 ighlight the potential of this compound as a neuroprotectant.
9 se outcome may accelerate the development of neuroprotectants.
10 quinazoline scaffolds that themselves act as neuroprotectants.
11 ariety of antioxidants have been examined as neuroprotectants.
12 opted recently to investigate four candidate neuroprotectants.
13 17beta-estradiol and its analogs are potent neuroprotectants.
14 K-1 is a target for general anaesthetics and neuroprotectants.
15 licity-properties favoring their efficacy as neuroprotectants.
16 therapeutic potential as anticonvulsants and neuroprotectants.
18 oxidase and elucidated the role of CK2 as a neuroprotectant after oxidative insults to the brain.
19 s less potent or altogether ineffective as a neuroprotectant after sham surgery compared to OVX or af
23 this study supports IV Ca/Mg as an effective neuroprotectant against oxaliplatin-induced cumulative s
24 xifen (TMX), has been shown to function as a neuroprotectant against the nigrostriatal dopaminergic (
25 ng interest in the functions of estrogens as neuroprotectants against neurodegenerative diseases incl
26 ty and that DMF could serve as an adjunctive neuroprotectant and HIV disease modifier in ART-treated
28 work we establish maprotiline as a candidate neuroprotectant and HRH1 as a potential therapeutic targ
31 t QXs 12a and 12e are also active in vivo as neuroprotectants and also have antinociceptive activity
33 orms, which will be invaluable for selecting neuroprotectants and elucidating their molecular mechani
34 pendent on the impact of the insult and that neuroprotectants are more likely to benefit a patient in
35 r (H3R) were obtained by optimization of the neuroprotectant ASS234 by incorporating generally accept
37 rophic factor (BDNF) is a well-known retinal neuroprotectant, but its effectiveness is limited: highe
39 ccumbens; and (4) estrogen may function as a neuroprotectant by reducing the uptake of neurotoxin int
43 e, the authors tested the effects of sex and neuroprotectant exposure on the behavioral consequences
47 that cobalamin may function as an endogenous neuroprotectant for RGCs through a superoxide-associated
49 , suggesting that IGF-1 may have a role as a neuroprotectant for surviving neurons and signal for loc
50 hesized that SIRT1 might serve as a critical neuroprotectant for wake neurons in young animals but th
52 need for novel, biocompatible, and effective neuroprotectants for the treatment of neurodegenerative
55 primate stroke models, hundreds of putative neuroprotectants have been evaluated in preclinical mode
57 gas xenon has been shown to be an effective neuroprotectant in a variety of in vitro and in vivo mod
58 an NMDA antagonist, thereby functioning as a neuroprotectant in a wide range of pathological states.
59 ines the studies indicating that estrogen is neuroprotectant in animal models and explores potential
65 unction, methylene blue (MB) is an effective neuroprotectant in many neurological disorders (e.g., Pa
68 se Mn-SOD gene and plays a crucial role as a neuroprotectant in regulating levels of reactive oxygen
69 ed protein C has been shown to be a powerful neuroprotectant in stressed neurons and in hypoxic brain
71 h PEDF as both a metastatic suppressor and a neuroprotectant in the brain, highlighting its role as a
73 trophic factor (BDNF), a particularly potent neuroprotectant in the mammalian eye and the basis of ou
75 pothesis that 17beta-estradiol (betaE2) is a neuroprotectant in the retina, using two experimental ap
77 prevents oxidative cell death and acts as a neuroprotectant in vivo, prompting its evaluation to tre
78 e inert gases helium and xenon are effective neuroprotectants in a model for traumatic brain injury,
79 ded that the lack of efficacy of a number of neuroprotectants in clinical trials may well be a conseq
80 reclinical stage and the testing of putative neuroprotectants in enriched clinical studies of patient
82 reatment with elevated concentrations of the neuroprotectants KCl or cAMP at the time of deprivation
83 Cryab is an endogenous anti-inflammatory and neuroprotectant molecule produced after stroke, whose be
85 wever, while adenosine acts as an endogenous neuroprotectant, NO is believed to be the effector of gl
86 eroid hormone estrogen (E) can function as a neuroprotectant of nigrostriatal dopaminergic (NSDA) neu
87 ard to estradiol's capacity to function as a neuroprotectant of the nigrostriatal dopaminergic system
88 corpus striatum, and in this way serve as a neuroprotectant of the nigrostriatal dopaminergic system
89 he effects of mild hypothermia, an effective neuroprotectant, on fluid shifts, cerebral perfusion and
90 nt strategies involving fibrates, connexins, neuroprotectants, photobiomodulation, and anti-inflammat
92 nsufficient data on the use of the potential neuroprotectant selegiline and patients on pramipexole i
95 ts identify Cdc25A as a potential target for neuroprotectant strategy for the treatment of delayed is
97 ated fatty acids (such as arachidonic acid), neuroprotectants (such as riluzole) and volatile and gas
98 ecause of decreased availability of IGF-1, a neuroprotectant that decreases with advancing age and is
99 with post-synaptic density protein 95, is a neuroprotectant that is effective in preclinical stroke
101 l cells (ECs) in the brain, functioning as a neuroprotectant through the activation of the neurotroph
102 indicates that estrogens could be used as a neuroprotectant to prolong the therapeutic window of thr
103 e, suggesting that NGB acts as an endogenous neuroprotectant to reduce oxidative stress and improve m
104 oration of emerging strategies, ranging from neuroprotectants to dose-sparing radiotherapy techniques
107 history, we persist in testing new, putative neuroprotectants using the same concepts, approaches, an
108 h a view to identify novel and biocompatible neuroprotectants, we designed nucleoside 5'-thiophosphat
109 ures of both helium and xenon were effective neuroprotectants when applied in addition to 1 atm of ai
111 (chlorpromazine & promethazine) as additive neuroprotectants, with the aim of augmenting its efficac